BACKGROUND: Affective neuropsychiatric symptoms (aNPS: depression, anxiety, apathy, irritability) have been linked to increased dementia risk. However, less is known whether this association is independent of Alzheimer's disease (AD) pathophysiology. OBJECTIVE: To investigate the contribution of early aNPS to dementia risk in cognitively normal (CN) older adults and mild cognitive impairment (MCI) patients, with and without AD biomarker abnormality. METHODS: Participants included 763 community-dwelling, stroke-free older adults identified as CN and 617 with MCI at baseline, drawn from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database. Baseline assessments included a neuropsychological battery, the Neuropsychiatric Inventory (NPI), and apolipoprotein E ɛ4 (ApoE4) genotyping. A participant subset completed cerebrospinal fluid (CSF) AD biomarker assessment. Time to progression to dementia was measured based on months at follow-up when an individual was diagnosed with dementia, over the follow-up period of 48 months. RESULTS: Latent class analysis identified 3 subgroups of older adults in CN and MCI, indicated by the baseline profiles of neuropsychiatric symptoms (NPS). Subgroups with higher aNPS were at increased risk of progression to dementia in both CN (HR = 3.65, 95% CI [1.80, 7.40]) and MCI (HR = 1.52, 95% CI [1.16, 2.00]; HR = 1.86 [1.05, 3.30]) groups, adjusting for age, sex, global cognition, and ApoE4, compared with their counterparts with minimal NPS. There was no difference between higher aNPS and minimal NPS subgroups in their CSF AD biomarker profiles. CONCLUSION: Findings suggest that aNPS may represent a neurobiological vulnerability that uniquely contribute to the dementia risk, independent of AD biomarker profiles.
BACKGROUND: Affective neuropsychiatric symptoms (aNPS: depression, anxiety, apathy, irritability) have been linked to increased dementia risk. However, less is known whether this association is independent of Alzheimer's disease (AD) pathophysiology. OBJECTIVE: To investigate the contribution of early aNPS to dementia risk in cognitively normal (CN) older adults and mild cognitive impairment (MCI) patients, with and without AD biomarker abnormality. METHODS:Participants included 763 community-dwelling, stroke-free older adults identified as CN and 617 with MCI at baseline, drawn from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database. Baseline assessments included a neuropsychological battery, the Neuropsychiatric Inventory (NPI), and apolipoprotein E ɛ4 (ApoE4) genotyping. A participant subset completed cerebrospinal fluid (CSF) AD biomarker assessment. Time to progression to dementia was measured based on months at follow-up when an individual was diagnosed with dementia, over the follow-up period of 48 months. RESULTS: Latent class analysis identified 3 subgroups of older adults in CN and MCI, indicated by the baseline profiles of neuropsychiatric symptoms (NPS). Subgroups with higher aNPS were at increased risk of progression to dementia in both CN (HR = 3.65, 95% CI [1.80, 7.40]) and MCI (HR = 1.52, 95% CI [1.16, 2.00]; HR = 1.86 [1.05, 3.30]) groups, adjusting for age, sex, global cognition, and ApoE4, compared with their counterparts with minimal NPS. There was no difference between higher aNPS and minimal NPS subgroups in their CSF AD biomarker profiles. CONCLUSION: Findings suggest that aNPS may represent a neurobiological vulnerability that uniquely contribute to the dementia risk, independent of AD biomarker profiles.
Authors: Reisa A Sperling; Paul S Aisen; Laurel A Beckett; David A Bennett; Suzanne Craft; Anne M Fagan; Takeshi Iwatsubo; Clifford R Jack; Jeffrey Kaye; Thomas J Montine; Denise C Park; Eric M Reiman; Christopher C Rowe; Eric Siemers; Yaakov Stern; Kristine Yaffe; Maria C Carrillo; Bill Thies; Marcelle Morrison-Bogorad; Molly V Wagster; Creighton H Phelps Journal: Alzheimers Dement Date: 2011-04-21 Impact factor: 21.566
Authors: Alireza Showraki; Geetanjali Murari; Zahinoor Ismail; Joseph J Barfett; Luis Fornazzari; David G Munoz; Tom A Schweizer; Corinne E Fischer Journal: J Alzheimers Dis Date: 2019 Impact factor: 4.472
Authors: Stefan Van der Mussele; Erik Fransen; Hanne Struyfs; Jill Luyckx; Peter Mariën; Jos Saerens; Nore Somers; Johan Goeman; Peter P De Deyn; Sebastiaan Engelborghs Journal: J Alzheimers Dis Date: 2014 Impact factor: 4.472
Authors: Bernice Gulpers; Inez Ramakers; Renske Hamel; Sebastian Köhler; Richard Oude Voshaar; Frans Verhey Journal: Am J Geriatr Psychiatry Date: 2016-07-04 Impact factor: 4.105
Authors: Grace J Lee; Po H Lu; Xue Hua; Suh Lee; Stephanie Wu; Ken Nguyen; Edmond Teng; Alex D Leow; Clifford R Jack; Arthur W Toga; Michael W Weiner; George Bartzokis; Paul M Thompson Journal: Biol Psychiatry Date: 2012-02-08 Impact factor: 13.382
Authors: Yonas E Geda; Rosebud O Roberts; Michelle M Mielke; David S Knopman; Teresa J H Christianson; Vernon S Pankratz; Bradley F Boeve; Ondrej Sochor; Eric G Tangalos; Ronald C Petersen; Walter A Rocca Journal: Am J Psychiatry Date: 2014-05 Impact factor: 18.112
Authors: Debby Van Dam; Yannick Vermeiren; Alain D Dekker; Petrus J W Naudé; Peter P De Deyn Journal: Curr Alzheimer Res Date: 2016 Impact factor: 3.498
Authors: Alexandra König; Elisa Mallick; Johannes Tröger; Nicklas Linz; Radia Zeghari; Valeria Manera; Philippe Robert Journal: Eur Psychiatry Date: 2021-10-13 Impact factor: 5.361